Skip to main content

Axsome Therapeutics, Inc.

AXSM
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001579428

In the last 90 days, Axsome Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 505 institutions reported holding it in 13F filings for Q2 2026, worth $9.34B in total; no superinvestor holds it.

Holders of 5% or more of AXSM

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Axsome Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Axsome Therapeutics, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

3 Schedule 13D and 13G filings on Axsome Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on AXSM
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20258:02 AM ETRTW Investments, LPand 1 other13G/A3.10%1.52M shares−2.90 ppfrom 6.00%Below 5%Jun 30, 2025SEC
May 15, 20258:09 AM ETRTW Investments, LPand 1 other13G/A6.00%2.92M shares−2.40 ppfrom 8.40%Mar 31, 2025SEC
Feb 14, 20259:00 AM ETRTW Investments, LPand 1 other13G/A8.40%4.05M shares–Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Axsome Therapeutics, Inc. shares.

No Form 144 notices for Axsome Therapeutics, Inc. are on file.